SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH.

Wendy`s Co - Ordinary Shares - Class A

Wendy's Co

Wendy's is trending as investors digest reports that activist investor Nelson Peltz's Trian Partners is preparing a bid to take the burger chain private. While the community is actively debating the potential buyout premium and its impact on the high short interest, others are focused on the company's operational challenges and the ongoing push-and-pull between retail bulls and short sellers.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is surging as investors cheer a stellar earnings report that highlighted massive year-over-year revenue growth and substantial new contract wins in the AI cloud sector. The stock is currently experiencing a significant short squeeze, with the community actively rallying against bearish sentiment and celebrating the company's ability to capitalize on intense AI infrastructure demand.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer is surging following a blowout earnings report featuring strong revenue growth and massive forward guidance, which has spurred intense community debate over a potential short squeeze against heavily bearish positioning. Investors are aggressively discussing the disconnect between the company's strong AI infrastructure demand and its relatively low valuation, while monitoring how Wall Street analysts adjust their price targets to keep pace with the company's growth.

RUM Group, Inc. engages in operating an online neutral video platform. It operates through the following geographical segments: United States, Canada, and Other. The company was founded in October 2013 by Chris Pavlovski and is headquartered in Longboat Key, FL.

RUM Group Inc. - Ordinary Shares - Class A

RUM Group Inc.

Rumble is trending as the market reacts to record quarterly revenue growth and an aggressive Q3 guidance that signals a major pivot toward AI infrastructure. The community is focused on the impact of the Northern Data acquisition, with intense debate centering on whether the companys rapidly scaling AI revenue and 250MW of potential power capacity justify a squeeze against significant short interest.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is trending as investors digest a series of positive clinical updates and institutional accumulation, with the community actively debating the company's timeline for BLA submission and the significance of upcoming biomarker data. While some voices express caution regarding the long-term cash burn and regulatory hurdles, the prevailing discussion focuses on the stock's potential for a re-rating as it approaches a anticipated Q4 BLA filing.

Firefly Aerospace, Inc. engages in the design and manufacture of space launch vehicles. The company was founded by Thomas E. Markusic, Mark Watt, and Max Polyakov in January 2017 and is headquartered in Leander, TX.

Firefly Aerospace Inc.

Firefly Aerospace is seeing increased volatility as investors weigh the company's strong backlog and recent contract wins against broader sector pressure from SpaceX's market dominance and upcoming lockup expirations. Community discussion remains focused on long-term growth potential and deep value opportunities, with many traders closely monitoring for a breakout ahead of the next earnings report.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Dallas, TX.

United States Antimony Corp.

United States Antimony Corp. is seeing heightened volatility and social media discussion following a sharp decline after missing quarterly revenue guidance due to lower market prices. Investors are closely debating the company's long-term potential as a critical U.S. mineral supplier, with many community members focusing on the need for government-backed price floors and upcoming operational catalysts to drive a recovery.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras Systems is seeing intense retail focus and high intraday volatility as investors debate its valuation and future growth prospects amid recent partnerships and earnings anticipation. While bulls highlight its AI inference speed and potential as a key infrastructure player, skeptics remain cautious due to lock-up expirations, concentrated client exposure, and elevated valuation concerns.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovin is experiencing significant volatility as investors weigh a post-earnings valuation pullback against the companys robust 50%+ year-over-year growth and strong cash flow metrics. While community sentiment is heavily divided between those viewing the decline as a generational buying opportunity and those concerned by bearish analyst downgrades, active discussion remains focused on the company's long-term profitability and the potential for a rebound driven by its proprietary AI-powered ad engine.

Lumentum Holdings, Inc. engages in the provision of optical and photonic products. It operates through the Cloud and Networking, and Industrial Tech segments. The Cloud and Networking segment refers to a portfolio of optical and photonic components, modules, and subsystems. The Industrial Tech segment includes solid-state lasers, kilowatt-class fiber lasers, ultrafast lasers, diode lasers, and gas lasers. The company was founded in 1979 and is headquartered in San Jose, CA.

Lumentum Holdings Inc

Lumentum Holdings ($LITE) is trending following a robust quarterly performance that exceeded estimates and prompted positive revisions to guidance, signaling strong ongoing demand for its high-speed optical networking solutions in AI data centers. Investors and community members are actively discussing the stock's volatility and its status as a key indicator for the broader photonics sector, while also evaluating how current supply-demand dynamics and sector-wide capacity expansions impact its long-term growth trajectory.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ImmunityBio is trending following the appointment of former World Bank President Dr. Jim Yong Kim as Vice Chairman, a strategic move the community views as a major signal for global expansion and increased institutional credibility. Investors are actively discussing the stock's potential for a massive breakthrough, specifically focusing on the company's platform, the recent increase in institutional holdings by BlackRock, and the anticipation of further global partnerships and regulatory approvals.

ImmunityBio Appoints Dr. Jim Yong Kim, Former World Bank President and Global Health Leader, as Vice Chairman

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that Dr. Jim Yong Kim has joined the company as Vice Chairman. Dr. Kim will serve in a newly created Office of the Executive Chairman, where he will focus on strengthening the company's international and...

IBRX Q2 Earnings & Sales Beat Estimates on Strong Anktiva Uptake

ImmunityBio beat Q2 earnings and revenue estimates as record Anktiva sales and continued adoption fuel growth, with more regulatory milestones ahead.

Pfizer, Merck, Amgen Double Down On Cancer And Send Takeover Buzz Around SLS And IBRX Into Overdrive

Equity

IBRX and SLS align with Big Pharma’s cancer push, fueling retail partnership and buyout speculation.

IBRX Founder Soon-Shiong Bets On Anktiva's Next Growth Phase — ImmunityBio Posts Record Q2 Sales

ImmunityBio’s record quarterly revenue of $51.2 million beat Wall Street’s estimates of $49.7 million, driven by the increased sales of Anktiva.


ImmunityBio (IBRX) Reports Q2 Loss, Beats Revenue Estimates

ImmunityBio (IBRX) delivered earnings and revenue surprises of +11.11% and +5.76%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

ImmunityBio Reports Record Q22026 Net Product Revenue of $50.7Million, Up 92% Year-Over-Year; First-Half Revenue Up 121% to $94.8Million

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage biotechnology company, today announced financial and operational results for the second quarter ended June 30, 2026. Net product revenue reached $50.7 million, representing 92% year-over-year growth and 15% sequential growth from the first...

IBRX Stock Sees Sharp UAE-Driven Jump Followed By Early August Pullback

On July 29, UAE regulators approved ImmunityBio’s main cancer drug ANKTIVA for two indications, sparking a rally the next day. 


Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates

Stoke Therapeutics (STOK) delivered earnings and revenue surprises of -13.42% and +69.55%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Biotech Stocks Need A Shot In The Arm After Brutal July: Could AstraZeneca-Bristol Myers Megadeal Be The Cure?

A potential AstraZeneca-Bristol Myers deal worth $400 billion would create one of the world’s largest drugmakers and combine major cancer franchises.

Nasdaq, S&P 500 Futures Rise: Microsoft Lifts AI Mood, Meta Sinks, Investors Brace For Apple, Amazon And PCE – Why MU, IBRX, CAPR, SBUX Are In Focus

Data on Stocktwits showed that retail sentiment remains ‘bearish’ on SPY and QQQ. 



ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

Neutral Sentiment

$SLS

$ONDS

$IBRX

$PYPL

Which of these trending stocks are you most bullish on right now - $SLS, $ONDS, $IBRX, or $PYPL?

Stocktwits

SELLAS Life Sciences Group Inc

Ondas Inc

PayPal Holdings Inc

Which of these trending stocks are you most bullish on right now - 

Stocktwits Polls

The hiring of former World Bank President Jim Yong Kim as Vice Chairman is viewed by investors as a major strategic catalyst for global expansion.

Traders are closely tracking data showing significant reduction in short interest as millions of shares are covered.

Discussion centers on the increasing stake of major asset managers like Blackrock, seen as a sign of confidence in long-term potential.

Bullish sentiment highlights the potential to bypass FDA delays by scaling clinical success into international markets like the UAE and Saudi Arabia.

Investors express frustration over the current lack of volume while anticipating a massive move fueled by upcoming trial catalysts.

Current Price	$7.66
Prev Close	$7.60
Open	$7.71
Dividend Yield	0.00%
50-Day Moving Average	$7.62
Beta	1.79
Avg. Volume	10.08M
PE Ratio	-8.90

52-Week High	$12.43
52-Week Low	$1.95
Market Capitalization	$8.05B
EPS (Annual)	-$0.382
Price to Book	-7.65
Revenue Per Employee	$163,947.90

Feed

News

Sentiment

Earnings

Fundamentals

Info